Acute Coronary Syndrome. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
Conditions
Interventions
Intervention 1: Patients in the intervention group will receive 20 mg of dapagliflozin immediately after randomization and before entering the cath lab, followed by 10 mg daily for a minimum of 48 hou
Sponsors
Rajaie Cardiovascular Medical and Research Institute
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients over 18 years old hospitalized with acute coronary syndrome (i.e. ST elevation or NST elevation myocardial infarction or unstable angina) diagnosis and candidates for coronary angiography or angioplasty Signed informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Patients previously treated with SGLT2 inhibitor drugs Creatinine clearance less than 25 ml/min Chronic liver disease and cirrhosis (Child-Pugh C) Drug allergy or history of severe hypersensitivity to dapagliflozin or its components Non-consent to participate in the study History of recurrent urinary tract infections History of ketoacidosis Pregnancy or breastfeeding Type 1 diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ?The incidence of contrast- associated acute kidney injury defined by KDIGO criteria . Timepoint: 7 days after intervention. Method of measurement: Lab findings (serum creatinine) and urine output. | — |
Secondary
| Measure | Time frame |
|---|---|
| Need for renal replacement therapy. Timepoint: 7 days? after intervention. Method of measurement: Clinical records.;Length of hospitalization. Timepoint: Until discharge from hospital. Method of measurement: Clinical records.;Incidence of adverse drug reactions. Timepoint: 7 days after randomization. Method of measurement: Clinical records. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHessam kakavand
Iran University of Medical Sciences
Outcome results
None listed